Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Current biologics for treatment of biliary tract cancers
Diana Y. Zhao
,
Kian Huat Lim
Division of Hospital Medicine
Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
Section of Molecular Oncology & Developmental Therapeutics
DBBS - Molecular Cell Biology
DBBS - Immunology
DBBS - Cancer Biology
Research output
:
Contribution to journal
›
Review article
›
peer-review
38
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current biologics for treatment of biliary tract cancers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Biliary Tract Cancer
100%
Gallbladder Cancer
66%
Intrahepatic Cholangiocarcinoma (iCCA)
66%
Extrahepatic Cholangiocarcinoma
66%
Mitogen-activated Protein Kinase
33%
Treatment Options
33%
Clinical Outcomes
33%
Clinical Trials
33%
Effective Treatment
33%
Next-generation Sequencing
33%
Advanced Disease
33%
Malignancy
33%
Epithelial Cells
33%
Paucity
33%
Isocitrate Dehydrogenase 1 (IDH1)
33%
New Therapies
33%
Histological Subtypes
33%
Metastatic Disease
33%
Early Disease
33%
Advanced or Metastatic
33%
Site of Origin
33%
Targeted Therapeutics
33%
Molecular Signature
33%
Emerging Knowledge
33%
Systemic Chemotherapy
33%
Disease Biology
33%
Anatomic Site
33%
Dismal Prognosis
33%
Biliary Tree
33%
Complete Surgical Resection
33%
EGFR Pathway
33%
FGFR2 Fusion
33%
HER2 Pathway
33%
Medicine and Dentistry
Biological Product
100%
Cholangiocarcinoma
100%
Biliary Duct Cancer
100%
Diseases
75%
Cancer
50%
Gallbladder Cancer
50%
Biliary Tract Cancer
50%
Biological Marker
25%
Clinical Trial
25%
Metastatic Carcinoma
25%
Epithelial Cell
25%
Epidermal Growth Factor Receptor
25%
Next Generation Sequencing
25%
Mitogen-Activated Protein Kinase
25%
Fibroblast Growth Factor Receptor 2
25%
Surgery
25%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
100%
Biliary Tract Cancer
100%
Bile Duct Carcinoma
100%
Diseases
75%
Gallbladder Cancer
50%
Clinical Trial
25%
Biological Marker
25%
Chemotherapy
25%
Epidermal Growth Factor Receptor
25%
Metastasis
25%
Fibroblast Growth Factor Receptor 2
25%
Biochemistry, Genetics and Molecular Biology
Mitogen-Activated Protein Kinase
100%
Clinical Trial
100%
Next Generation Sequencing
100%
Epidermal Growth Factor Receptor
100%
Fibroblast Growth Factor Receptor 2
100%